
Shalini Subramaniam
@shalsubra
Medical Oncologist @SWSLHD | PhD Student @Sydney_Uni | Research Fellow @TrialsCentre | Interests: lung/GU/breast cancer; improving doctor-patient communication
ID: 121351107
09-03-2010 06:48:16
91 Tweet
223 Followers
282 Following

Lovely work from Shalini Subramaniam Patients' perception of the benefits of palliative systemic therapy for advanced cancer - Subramaniam - 2024 - Internal Medicine Journal - Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/im… Belinda Kiely martinst

A team effort with Anuradha Vasista @brownjlauren Belinda Kiely et al 📝 🙌 simple multiples of the median OS from RCTs can be used to estimate and communicate #prognosis for patients with advanced breast cancer starting endocrine therapy doi.org/10.1111/ajco.1… 🧵 1/X

Calling Australian Oncologists at MOGA and beyond! Contribute your perspectives on the time toxicity of palliative systemic treatments by taking our 10 minute survey - more in the poster hall at #MOGA24 Medical Oncology Group of Australia Follow the link to participate: redcap.slhd.nsw.gov.au/surveys/?s=EFD…



Is metastatic cancer curable? Seeking perspectives of oncologists and trainees who treat solid tumours. 🔗: tinyurl.com/vfcwjmac ⏱️: <15mins ✅: med/clin oncs from 🌎🌍🌏 Medical Oncology Group of Australia ausyoungoncs ANZUP Thoracic Oncology Group of Australasia OncoAlert #OncTwitter



Why do the TheraP and VISION trials show different effects of Lu-177 PSMA on survival in advanced prostate cancer? It may be due to different comparison treatments. jamanetwork.com/journals/jaman… Martin Stockler Ian Marschner Michael Hofman Ian Davis (Bluesky @profiand) Louise Emmett

Being presented at ASCO #GU25 ⬇️ Overall survival & QOL results from ENZA-p: [177Lu]Lu-PSMA-617 plus enzalutamide vs enzalutamide in metastatic castration-resistant #prostatecancer Louise Emmett Ian Davis Michael Hofman Martin Stockler ANZUP bit.ly/3ExZgPI

Congrats ANZUP #ENZAp study positive OS & QoL results presented by Louise Emmett @ASCSO #GU25 & published The Lancet. Movember Australia Cancer Australia Astellas Europe #ARTnet St Vincent's Clinic Roy Morgan Novartis MIM Software GenesisCareUK ANSTO NHMRC CTC Ian Davis




PSMA-PET total tumour volume is prognostic for overall survival in mCRPC. thelancet.com/journals/lanon… PSMA-PET value extends beyond selection for PSMA-RLT therapy in metastatic prostate cancer. urotoday.com/video-lectures… ANZUP @trialscentre Prostate Cancer Foundation Movember Australia



Access the full paper on PSMA-PET prognostic and predictive biomarkers in ENZAp with the link below: ANZUP LancetOncology NHMRC CTC Movember Australia Prostate Cancer Foundation authors.elsevier.com/a/1lWie5EIIgTS…

